Baxter Bros Inc. Buys 3,942 Shares of Eli Lilly and Company $LLY

Baxter Bros Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 319.4% in the 3rd quarter, Holdings Channel.com reports. The firm owned 5,176 shares of the company’s stock after acquiring an additional 3,942 shares during the quarter. Baxter Bros Inc.’s holdings in Eli Lilly and Company were worth $3,949,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Laurel Wealth Advisors LLC raised its stake in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank purchased a new position in shares of Eli Lilly and Company in the second quarter worth about $8,827,714,000. Vanguard Group Inc. raised its position in shares of Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after purchasing an additional 765,010 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Eli Lilly and Company by 13.4% during the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock valued at $3,715,913,000 after buying an additional 564,736 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research note on Monday, November 10th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Finally, HSBC reaffirmed a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Four analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,155.36.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zacks raised quarterly and full‑year EPS estimates for LLY, reflecting stronger-than-expected GLP-1 and franchise momentum which supports earnings upside. Zacks raises LLY estimates
• Positive Sentiment: Forbes outlines three possible catalysts that could trigger an LLY rally (pipeline readouts, successful oral GLP‑1 launch execution and M&A/partnerships), providing a roadmap for upside if Lilly executes. 3 Catalysts That Can Start An Eli Lilly Stock Rally
• Positive Sentiment: High‑profile bullish commentary (e.g., Jim Cramer) and positive Phase‑3/clinical data updates (breast cancer, EMBER‑3 imlunestrant results) keep long‑term conviction intact for growth beyond obesity drugs. Jim Cramer on Lilly
• Positive Sentiment: Broker support remains: Bank of America and others maintain Buy/overweight views and some firms have raised price targets based on eventual realization of obesity‑drug earnings. This provides analyst backing for potential rebounds. BofA maintains Buy on Eli Lilly
• Neutral Sentiment: Sector rotation into healthcare/XLV increases passive demand for LLY (it’s a large ETF holding), supporting structural investor interest even amid short‑term volatility. Sector Rotation: 2 Smart Money Moves for 2026
• Neutral Sentiment: Deal speculation (reported meetings with Abivax/French officials) and ongoing partnership chatter could be upside optionality but are early-stage and uncertain. Abivax soars on Lilly meeting report
• Negative Sentiment: Major near-term headwind: the FDA approved Novo Nordisk’s oral Wegovy pill — the first daily oral obesity drug — giving Novo a first‑mover advantage that could pressure Lilly’s orforglipron launch timing/market share and is driving the stock pullback. Novo Nordisk weight-loss drug wins US approval as a daily pill
• Negative Sentiment: Market reaction and commentary: multiple outlets report LLY shares falling as investors re‑price competitive risk and potential slower or lower peak sales for Lilly’s oral GLP‑1; near‑term investor focus will be on comparative efficacy, launch execution, and pricing dynamics. Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,070.80 on Wednesday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The stock has a market cap of $1.01 trillion, a price-to-earnings ratio of 52.39, a PEG ratio of 1.09 and a beta of 0.37. The stock’s 50 day simple moving average is $971.08 and its two-hundred day simple moving average is $835.68.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.